JPMorgan Upgrades Alnylam Pharmaceuticals (ALNY) to Overweight
November 9, 2017 4:37 AM
JPMorgan upgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Neutral to Overweight with a price target of $162.00 (from $86.00).Analyst Anupam Rama ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
